valneva canada
Valneva Canada Inc. is the wholly-owned Canadian commercial subsidiary of Valneva SE, marketing and distributing specialty prophylactic vaccines (DUKORAL®, IXCHIQ®, IXIARO®, KamRAB™) to Canadian healthcare professionals and patients in travel and tropical medicine.
- Company typePrivate
- Founded-
- HeadquartersKirkland, Canada
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
What valneva canada does
Valneva Canada Inc. is the wholly-owned Canadian commercial subsidiary of Valneva SE (NASDAQ Stockholm: VALN), a specialty vaccine company. Headquartered at 3535 Saint-Charles Blvd., Suite 600, Kirkland, Québec, the entity is responsible for marketing and distributing Valneva's prophylactic vaccines and third-party vaccines within Canada. Its portfolio comprises four products — DUKORAL® (oral inactivated cholera and LT-producing ETEC diarrhea vaccine), IXCHIQ® (live attenuated chikungunya vaccine, the world's first Health Canada-approved chikungunya vaccine), IXIARO® (inactivated adsorbed Japanese encephalitis vaccine), and KamRAB™ (human rabies immunoglobulin for post-exposure prophylaxis) — spanning oral, inactivated, live attenuated, and immunoglobulin platforms. The IXCHIQ® monograph was refreshed in January 2026, with a subsequent safety update in March 2026 covering medically frail individuals aged 65 and older.
The company operates an enterprise field-sales model targeting Canadian healthcare professionals — physicians, pharmacists, and nurses specializing in travel or tropical medicine — with a secondary consumer/end-patient segment. Distribution is conducted through direct sales to HCPs and Canadian pharmacies via prescription, supported by dedicated toll-free ordering (1-833-562-0262), medical inquiry and adverse-event reporting lines (1-855-356-0831; [email protected]), and fax ordering. Revenue is generated through one-time prescription-based vaccine sales; specific pricing is not publicly disclosed. Marketing channels include direct HCP communication and press release/news dissemination for regulatory milestones. The entity complies with Canadian privacy frameworks including PIPEDA and Québec's private-sector privacy statute, alongside GDPR, with data transfers to international servers consistent with a parent-controlled multinational operating model.
valneva canada firmographics
Firmographics- Name
- valneva canada
- Legal name
- Valneva Canada Inc.
- Website
- https://valneva.ca
- Company type
- Private
- Operating status
- Operating
- Short description
- Valneva Canada Inc. is the wholly-owned Canadian commercial subsidiary of Valneva SE, marketing and distributing specialty prophylactic vaccines (DUKORAL®, IXCHIQ®, IXIARO®, KamRAB™) to Canadian healthcare professionals and patients in travel and tropical medicine.
- Ownership category
- akta.pro rank
valneva canada industry classification
Industry- Product category
- Specialty Vaccines
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Travel & Tropical Disease Vaccines (HLAIAEAE)
- akta.pro secondary industries
- Immunoglobulins & Passive Immunization Biologics (IVIG, hyperimmune globulins, antitoxins) (HLAAAEAH), Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK), Immunization & Vaccine Clinics (HLAKAGAJ)
Keywords
Where valneva canada is headquartered
LocationHeadquarters
- HQ city
- Kirkland
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
valneva canada business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Marketing or Sales, Operations, Technology or R&D, Others
Revenue model
- Proprietary Vaccine Sales: Sale of proprietary vaccines including DUKORAL, IXCHIQ, and IXIARO for infectious disease prevention
- Third-Party Vaccine Distribution: Marketing and distribution of third-party vaccines in Canada
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Prescription vaccine products |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels2 records
valneva canada product offering
Product offeringCore offering
Valneva Canada Inc. is the Canadian commercial operations arm of Valneva SE, focused on the marketing and distribution in Canada of Valneva's proprietary prophylactic vaccines—DUKORAL®, IXCHIQ®, and IXIARO®—as well as third-party vaccines (including KamRAB™). The company serves Canadian healthcare professionals (physicians, pharmacists, and nurses specializing in travel or tropical medicine) and pharmacies with specialty vaccines for cholera, chikungunya, Japanese encephalitis, ETEC diarrhea, and rabies.
Product overview
Valneva Canada is a specialty vaccine company focused on marketing and distributing prophylactic vaccines for infectious diseases. The company offers a portfolio of four distinct vaccine products: DUKORAL® (oral cholera and ETEC diarrhea vaccine), IXCHIQ® (chikungunya vaccine - the world's first approved), IXIARO® (Japanese encephalitis vaccine), and KamRAB™ (rabies immunoglobulin). These products address unmet medical needs in travel medicine and infectious disease prevention.
Differentiator
Problem solved
Functional benefit
Brands
- DUKORAL®: Oral, Inactivated Cholera and LT-producing ETEC Diarrhea Vaccine
- IXCHIQ®
- IXIARO®
- KamRAB™
Products and services
- DUKORAL® Oral, inactivated vaccine providing active immunization against cholera and LT-producing ETEC diarrhea; administered as a liquid with buffer solution. Indicated for travelers and individuals at risk of these diarrheal diseases.
- IXCHIQ® Live, attenuated chikungunya vaccine for active immunization against the chikungunya virus in individuals 12 years of age and older; administered as a single dose. First Health Canada-approved chikungunya vaccine globally.
- IXIARO® Inactivated, adsorbed Japanese encephalitis vaccine for prevention of Japanese encephalitis disease in travelers and individuals at risk of exposure.
- KamRAB™ Rabies Immunoglobulin (Human) used for post-exposure prophylaxis against rabies infection following suspected exposure.
Companies that use valneva canada
Customer profileSegments2 records
Ideal customer profiles1 record
valneva canada technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
valneva canada partnerships and signals
Strategic signalScale indicators1 record
Recent moves3 records
Expansion highlights3 records
valneva canada competitors and assessment
Company assessmentBroad incumbents
- Merck Canada: Canadian vaccines arm of Merck & Co., distributing multiple established vaccines via Canadian healthcare professionals and pharmacies; competes in travel and infectious disease categories.
- Pfizer Canada: Canadian operations of Pfizer, a major global vaccine manufacturer with a broad portfolio including travel-related vaccines distributed through the same HCP and pharmacy channels in Canada.
- Sanofi Pasteur Canada: Canadian vaccines arm of Sanofi, the world's largest vaccine company. Markets a broad portfolio of travel (e.g., typhoid, rabies immunoglobulin alternatives) and routine vaccines in Canada through HCP and pharmacy channels.
- GSK Canada: Canadian subsidiary of GSK, a global vaccine leader with established travel and endemic-disease vaccines distributed through Canadian HCPs and pharmacies.
Direct peers
- Valneva SE: Parent company of Valneva Canada Inc.; publicly traded specialty vaccine company (NASDAQ Stockholm: VALN) developing and commercializing the same DUKORAL, IXCHIQ, and IXIARO vaccine portfolio globally. Direct parent and operational counterpart.
- Bavarian Nordic: Specialty vaccine company focused on infectious diseases with a travel/tropical and biosafety portfolio (e.g., rabies, smallpox/vaccinia). Closely comparable specialty-vaccine business model targeting similar public-health and travel indications.
- Emergent BioSolutions: Specialty vaccines and biologics company with a travel-medicine and infectious-disease portfolio (e.g., Vivotif typhoid, rabies immunoglobulin). Comparable niche-vaccine commercial focus and HCP channel.
Emerging players
- Moderna Canada: Canadian operations of Moderna, an mRNA-based vaccine developer with programs in emerging infectious diseases that could intersect with Valneva's travel/tropical disease portfolio.
- Bharat Biotech International: Indian vaccine manufacturer that has developed chikungunya vaccines (e.g., IXCHIQ competitor candidates) and a broad travel/endemic-disease portfolio; emerging competitor in chikungunya and tropical-disease space.
- Novavax: Vaccine developer with platform technology positioned for emerging infectious diseases and travel-related pathogens; potential adjacent competitor in specialty infectious-disease vaccines.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
valneva canada social profiles
Digital presencevalneva canada financial estimates
Financial estimateRevenue estimate
Valuation estimate
valneva canada leadership team
Management profileNumber of profiles
Profiles1 record
valneva canada funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
valneva canada M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about valneva canada
What does valneva canada do?
Valneva Canada Inc. is the Canadian commercial operations arm of Valneva SE, focused on the marketing and distribution in Canada of Valneva's proprietary prophylactic vaccines—DUKORAL®, IXCHIQ®, and IXIARO®—as well as third-party vaccines (including KamRAB™). The company serves Canadian healthcare professionals (physicians, pharmacists, and nurses specializing in travel or tropical medicine) and pharmacies with specialty vaccines for cholera, chikungunya, Japanese encephalitis, ETEC diarrhea, and rabies.
Is valneva canada a public or private company?
valneva canada is a private company. It is classified as corporate owned and is currently operating.
When was valneva canada founded?
valneva canada was founded in -1.
Where is valneva canada based?
valneva canada is headquartered in Kirkland, Canada, in the North America region.
How does valneva canada make money?
Two revenue lines are on record. Proprietary Vaccine Sales are the primary driver. The others are third-Party Vaccine Distribution.
Who are valneva canada's main competitors?
Broad incumbents on record are Merck Canada, Pfizer Canada, Sanofi Pasteur Canada and GSK Canada. Direct peers are Valneva SE, Bavarian Nordic and Emergent BioSolutions. Emerging players are Moderna Canada, Bharat Biotech International and Novavax.
Does valneva canada have an API?
No public API is recorded for valneva canada.
What industry is valneva canada in?
valneva canada's product category is Specialty Vaccines. Its primary akta.pro industry code is HLAIAEAE, Travel & Tropical Disease Vaccines, with a secondary code of HLAAAEAH, Immunoglobulins & Passive Immunization Biologics (IVIG, hyperimmune globulins, antitoxins). Its SIC code is 2834.